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Abstract
Background: Transthoracic echocardiography-assessed coronary flow velocity reserve (CFVR) evaluates coronary
microvascular arterial function. Coronary flow velocity measurements at baseline and during hyperemia are used to
calculate CFVR. Adenosine infusion induces hyperemia but it is not known if it causes a maximal response.
We hypothesized that pre-treatment with nitroglycerine before adenosine provocation enhances hyperemia.
Methods: Twenty-three healthy study subjects (mean age 27.5 ± 5.5, 35% women) underwent CFVR measurements
before and after pretreatment with sublingual nitroglycerine (0.5 mg). Hyperemia was induced by adenosine infusion
(140 μg/kg/min). In addition, the effect of nitroglycerin on left main coronary artery diameter was assessed.
Results: Pretreatment with nitroglycerine increased median CFVR from 3.6 (range 2.8–4.3) to 5.0 (4.1–6.0), p = 0.002.
The increase was caused by a marked reduction in baseline coronary flow velocity 17 (15–24) vs 27 (19–31)
cm/s, p < 0.0001) while hyperemic velocity remained unchanged (90 (68–116) vs 93 (75–105) cm/s, p = 0.48).
Nitroglycerin significantly dilated the left main coronary artery (from median 3.1 (2.7–3.6) mm to 3.8 (3.1–4.3)
mm, p = 0.018).
Conclusion: Pretreatment with nitroglycerine dilates coronary arteries and increases coronary flow velocity
reserve indicating that adenosine alone causes a submaximal hyperemia.
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Background
Transthoracic color Doppler echocardiography-assessed
coronary flow velocity reserve (CFVR) is an emerging
non-invasive method to quantify coronary microvascular
function and evaluate volumetric coronary flow reserve
(CFR) [1–4]. CFVR has opened up new possibilities to
explore cardiovascular physiology and to evaluate
responses to treatment, due to its good reproducibility
and low method-dependent variability if performed by
well-trained operators [5–7], and it has been shown that
low CFVR predicts epicardial coronary artery stenosis
[8–10] and cardiovascular events in different patient
populations [11–13]. CFVR is suitable for repeated
measurements of coronary function since it is non-
invasive, without radiation, easily accessed with a clinical
ultrasound device and is associated with acceptable
discomfort to the patient. With modern ultrasound
platforms it is also possible to non- invasively evaluate
size and morphology of small structures like certain
segments of coronary arteries [14, 15].
Mean coronary flow velocity at baseline and during
maximum hyperemia are used to calculate CFVR. Infu-
sion of the vasodilator adenosine is an established
method to induce hyperemia [16] and studies has sug-
gested 140 μg/kg/min as suitable dose [17]. Adenosine
acts mainly on small resistance vessels, but influences
also to a lesser degree epicardial arteries [18]. Even small
changes in epicardial vessel diameter would result in
alterations of flow velocity [19]. Thus, it is yet not
known whether CFVR due to adenosine-induced
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dilatation of epicardial vessels underestimate CFR, which
is a volumetric flow reserve.
It is possible that other vasodilators alone or in com-
bination with adenosine would induce an even higher
level of hyperemia [19]. Nitroglycerin (NTG) is a vaso-
dilator mainly acting on epicardial arteries [20, 21].
NTG may be used in combination with adenosine dur-
ing measurements of flow fraction reserve in connection
to coronary angiogram in patients with coronary artery
disease. In this context NTG is in combination with
adenosine used to maximize blood flow and prevent wire
induced artery spasm.
We hypothesized that pre-treatment with nitroglycerine
before adenosine provocation in CFVR measurements in
healthy volunteers enhances the hyperemia further in
comparison to adenosine alone, due to maximum dilata-
tion of not only the resistance vessels but also epicardial
arteries. In addition, we explored the effects of nitroglycer-
ine on basal coronary flow and coronary artery diameter
and assessed the reproducibility of repeated CFVR mea-




Twenty-three healthy volunteers (mean age 27.5 ±
5.5 years, 38% women) participated in the study. Inclusion
criteria were age 18–40 years, normal BMI and no chroni-
cal or acute illness requiring medication. Exclusion criteria
were history of asthma, chronic obstructive pulmonary
disease, anxiety disorder, and ongoing infection. Study
subjects characteristics are presented in Table 1.
Study design
All study subjects were investigated on two consecutive
days. The study protocol on each study day included
two sets of coronary flow velocity measurements at
baseline and during adenosine infusion. On the study
days all subjects were fasting for four hours and were
caffeine free for at least 24 h before the investigation.
On day 1 a suitable vessel segment of mid left anterior
descending artery (LAD) regarding measurement quality
and breathing interference was identified with transtho-
racic color doppler echocardiography. During the first
measurement (1:1), baseline coronary flow velocity was
recorded and thereafter adenosine infusion at a rate of
140 μg/kg/min was started. Hyperemic coronary flow
measurements were obtained during 5 min where the
highest recordings were registered. After completion of
the measurements, the adenosine infusion was paused.
After a ten minute washout period a new measurement
period was started (1:2) when new baseline measure-
ments were obtained before the adenosine infusion was
re-started at the same rate for new hyperemic measure-
ments. Heart rate and systolic blood pressure were
recorded every minute during adenosine infusion to
detect potential adverse reactions.
On day 2, two new measurements were performed
(2:1 and 2:2). The measurements were identical to the
procedures on day 1 with the exception that after five
minutes of the washout period between the two sets of
measurements 0.5 mg of sublingual nitroglycerine
(Recip, Jordbro, Sweden) was administrated to the study
subjects. Five minutes after nitroglycerine administration
new baseline measurements and adenosine–induced
hyperemic measurements were performed (period 2:2).
In a subgroup of nine subjects with good visualization of
the left main coronary artery, the diameter of the vessel was
measured before and after nitroglycerine administration.
Coronary blood flow velocity measurements
A Siemens Acuson platform equipped with a 4V1C
transducer with 3.5 MHz color Doppler frequency and
1.75 MHz spectral Doppler frequency (Siemens, Acuson
Sequoia 512, Mountainview) was used to measure coronary
flow velocity (CFV) in the mid to distal left anterior
descending coronary artery (LAD), in a slightly modified
apical two-chamber view. The same operator performed all
measurements to ensure minimum variability. CINE-loops
and Doppler images were stored for offline analysis using
Tomtec image analysis software (Image Arena 2.9.1,
Tomtec Imaging Systems, GmbH, Unterschleissheim,
Germany). CFVR was calculated as the ratio between mean
hyperemic CFV and mean baseline CFV. A typical record-
ing of coronary flow velocity at baseline without nitrogly-
cerine is shown in Fig. 1.
Diameter of the left main coronary artery
The left main coronary artery was visualized in a modi-
fied short axis view at the level of aortic root and a
Table 1 Study subjects characteristics. Number and percentage
or mean and standard deviation
Gender (female) 8 (35%)
Age (years) 27.5 ± 5.5
Weight (kg) 70.5 ± 9.4
Length (cm) 177.5 ± 7.9
Body mass index (kg/m2) 22.3 ± 2.2
White blood cell count (×109/L) 5.7 ± 1.1
Hemoglobin concentration (g/L) 141 ± 13
Left ventricular ejection fraction (%)
At rest 61 ± 6
During adenosine 66 ± 5
Heart rate (beats per minute
At rest 59 ± 10
During adenosine 84 ± 13
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CINE-loop of a full cardiac circle with a frame rate up to
70 frames/s was stored for offline measurements. The
diameter was measured as close as possible to the R- wave
and at the same location both at baseline and after
nitroglycerine administration.
Statistics
No data for a sample size calculation was available
before study start. The number of included subjects
are based on own experiences and similar studies.
Data was not normally distributed. Data are thus
presented as median and range. Wilcoxon matched
paired test was used to compare mean CFV, CFVR
and artery diameter before and after adenosine and
nitroglycerine administration. Friedman’s test was
used to compare the two baseline measurements on
day 1 and the baseline measurement on day 2.
Results
General
Twenty of the 23 subjects completed all four measure-
ments. One was excluded due to anxiety during adeno-
sine infusion and two were excluded due to difficulties
to get satisfying CFV measurements after NTG adminis-
tration, due to low CFV.
Baseline flow velocity
There was no significant difference in flow velocity
between the two baseline measurements on day one
(1:1 and 1:2) and the first baseline measurement on
day two (2:1), p = 0.82, Table 2. In contrast, baseline
flow velocity was significantly lower after nitroglycerine
administration (2:2) in comparison to the measurement
before nitroglycerine (2:1) and to the two measurements
on day 1, p < 0.001, Table 2.
Fig. 1 Recording of coronary flow velocities in an individual study subject. The velocities were recorded at baseline (a), at adenosine-induced
hyperemia (b), at baseline with nitroglycerine (c), and at adenosine-induced hyperemia with nitroglycerine (d)
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Coronary flow velocity during hyperemia
Maximum velocity during hyperemia was higher during
the second measurement period on day 1 (1:2) compared
to the first measurement the same day (1:1), p = 0.021),
Table 2. No significant differences in maximum velocity
during hyperemia were observed between the first
measurement on day 1 (1:1) and the first measure-
ment day 2 (2:1), p = 0.20. Maximum velocity during
nitroglycerine administration (measurement 2:2) did
not differ significantly compared with the measure-
ment without nitroglycerine on the same day (2:1) or
to the hyperemic measurements on the first day (1:1
and 1:2), p = 0.53, Table 2.
Coronary flow velocity reserve
CFVR during the different measurement periods are
shown in Fig. 2. There was no significant difference in
CFVR when comparing the first measurements on each
study day (measurement 1:1 and 2:1), 3.7 (2.3–7.2) vs.
3.6 (2.3–6.9), (p = 0.39). CFVR after nitroglycerine ad-
ministration (measurement 2:2) was significantly higher
than with only adenosine (measurement 2:1), 5.0 (2.4–9.2)
vs 3.6 (2.3–6.9), (p = 0.002) and significantly higher than at
the two measurements on day 1, 3.7 (2.3–7.2), (p < 0.001)
and 3.9 (2.5–7.3), (p = 0.007), respectively. CFVR was
significantly higher during the second measurement on
day 1 (1:2) than during the first measurement the same
day (1:1), (p = 0.018).
Effects of nitroglycerine on vessel diameter
Left main coronary artery dilated significantly after
nitroglycerine administration (from median 3.1 (2.7–3.6)
mm to 3.8 (3.1–4.3) mm, p = 0.018), Fig. 3.
Discussion
The main findings of the present study were that pre-
treatment with nitroglycerine before adenosine-induced
hyperemia significantly increased coronary flow velocity
reserve.
In the present study we hypothesized that pre-
treatment with nitroglycerine before adenosine provoca-
tion in CFVR measurements would enhance the
hyperemia further in comparison to adenosine alone.
This hypothesis was based on the known vasodilating
effects of nitroglycerine on epicardial arteries and clin-
ical experiences from fractional flow reserve (FFR) mea-
surements and myocardial scintigraphy where pretreatment
with NTG may be used to enhance hyperemia [20–22].
After administration of NTG, there was a reduction in
baseline coronary flow velocity (before hyperemia) by
approximately 30%. This reduction in flow velocity is
more likely a result of a dilatation of the epicardial arter-
ies, than due to a reduction of total blood flow, since the
same amount of blood at a constant flow in a larger
vessel leads to a reduction in velocity. The effect on
vessel diameter is supported by the present study where
the diameter of the left main coronary artery increased
with approximately 20% after NG administration. Our
baseline results thus confirm the results shown by
Takagi et al. [21] where they, using the same method-
ology, found that NTG administration caused a decrease
in coronary resting flow velocity and a dilatation of
epicardial arteries.
Table 2 Coronary flow velocity at baseline and during





Day 1, measurement 1 (1:1) 25 (20–31) 87 (72–93)
Day 1, measurement 2 (1:2) 25 (19–31) 97 (77–111)#
Day 2, measurement 1 (2:1) 27 (19–31) 93 (75–105)
Day 2, measurement 2
(after nitroglycerine) (2:2)
17 (15–24)*** 90 (68–116)
*** = p < 0.001 vs measurement 1:1, 1:2 and 2:1; # = p < 0.05 vs measurement 1:1
Fig. 2 Coronary flow velocity reserve (CFVR) at baseline and during
adenosine-induced hyperemia. NTG = nitroglycerine. * = p < 0.05,
** = p < 0.01, *** = p < 0.001
Fig. 3 Left main coronary artery diameter before and after
nitroglycerine administration
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During adenosine provocation after NTG administra-
tion one would expect a reduction of coronary blood
flow velocity, compared to adenosine provocation with-
out NTG, since NTG dilates epicardial vessels. Contrary
to this hypothesis, there was no significant change in
hyperemic coronary blood flow velocity when compared
to the measurement without nitroglycerine. This may be
interpreted as an increase in total blood flow through
the myocardium after the combination of NTG and
adenosine administration, compared to only adenosine.
Thus, our results suggest that NTG pretreatment
increased adenosine-induced coronary blood flow in
healthy volunteers, supporting that epicardial vessel
dilation is essential to cause maximal hyperemic flow.
The reduced baseline velocity resulted in a signifi-
cantly increased CFVR even though nitroglycerine did
not increase hyperemic blood flow velocity (Table 2).
From a methodological point of view, CFVR is a good
estimate of CFR only when the epicardial vessel diameter
is maintained before and during adenosine infusion. In
case epicardial vessels dilate in response to increased
shear stress e.g., following inceased flow during adeno-
sine challenge, CFV increase measured at the same
epicardial vessel site as at baseline may be underesti-
mating the true flow increase. This indicates that
CFVR with nitroglycerine in combination with adenosine
might give a better volumetric coronary flow reserve
(CFR) estimation and a more stable measurement routine
than hyperemia induced by adenosine alone [23].
The results of the present study also demonstrate that
the reproducibility of flow velocity measurements is
satisfactory since the baseline measurements both at
the same day and between the two study days did not
differ significantly. This indicates that non.invasive
flow velocity measurements are stable and can be
used to detect even relatively small changes in flow
velocity over time. A low intraindividual variability
over time is a key factor for using this technique to
evaluate possible changes in coronary flow. However,
there was one potentially important exception. The
flow velocity during adenosine-induced hyperemia was
significantly higher during the second measurement
period on day 1 in comparison to the first measure-
ment the same day. The wash-out period between the
two measurements was only 10 min and it is possible
that the effects had not fully ceased, even though the
half life of adenosine is only a few seconds. Alterna-
tive explanations include upregulation of adenosine
receptors or increased sympathicus drive. The latter
explanation may be less likely since basal flow and
heart rate was unaltered between the two measure-
ments. Independently of the reason, a longer washout
period than 10 min can be recommended if repeated
adenosine- induced hyperemic periods are required.
Limitations
The present study had some limitations. The size of the
study population was limited. In particular, left main
diameter was measured only in eight patients. This may
reduce the validity of our observation. However, the 20%
difference between left main diameter before and after
nitroglycerine administration is within what previously
have been reported (8–25%) [21, 24]. A further limita-
tion is that the off line measurements were not blinded
to the operator. Finally, the study was performed in a
young, healthy population with healthy coronary arteries
and it is thus unclear whether the results can be applied
on patients with cardiac disease. A prospective study
with a larger number of subjects in a relevant patient
population with manifested coronary artery disease
would therefore be desirable.
Conclusion
Pre-treatment with nitroglycerine before adenosine infu-
sion could be a possible way to minimize the difference
between CFVR and CFR. It could also ensure maximal
coronary artery dilatation resulting in a more accurate
way of evaluating maximal coronary flow reserve.
Abbrevations
CFR: Coronary flow reserve; CFV: Coronary flow velocity; CFVR: Coronary flow




This work was supported by University of Gothenburg. The sponsor had no
influence on the analysis and interpretation of data, in the writing of the
report, or in the decision to submit the paper for publication.
Authors’ contributions
AW designed the study, collected and analyzed data and wrote the first draft
of the manuscript. AJ analyzed the data and revised the manuscript. LMG
designed the study, collected and analyzed data and revised the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
The study protocol was approved by the Regional Ethical Review Board in
Gothenburg, Sweden (number 449–06).
All participants signed a consent form after oral and written information.
All data generated or analysed during this study are included in this
published article.
Author details
1Dept of Molecular and Clinical Medicine, Institute of Medicine at
Sahlgrenska Academy, University of Gothenburg, 41345 Gothenburg,
Sweden. 2Department of Cardiology, Sahlgrenska University Hospital, 41345
Gothenburg, Sweden. 3Department of Cardiothoracic Surgery, Sahlgrenska
University Hospital, 41345 Gothenburg, Sweden. 4AstraZeneca R & D, 43150
Molndal, Sweden.
Received: 23 August 2016 Accepted: 22 November 2016
Wittfeldt et al. Cardiovascular Ultrasound  (2016) 14:48 Page 5 of 6
References
1. Hozumi T, Yoshida K, Akasaka T, Asami Y, Ogata Y, Takagi T, et al. Noninvasive
assessment of coronary flow velocity and coronary flow velocity reserve in the
left anterior descending coronary artery by Doppler echocardiography:
comparison with invasive technique. J Am Coll Cardiol. 1998;32:1251–9.
2. Caiati C, Zedda N, Montaldo C, Montisci R, Iliceto S. Contrast-enhanced
transthoracic second harmonic echo Doppler with adenosine: a noninvasive,
rapid and effective method for coronary flow reserve assessment. J Am Coll
Cardiol. 1999;34:122–30.
3. Saraste M, Mikkola J, Hartiala J. Transthoracic color Doppler echocardiography:
a new way to diagnose coronary artery disease. Echocardiography. 2001;18:
509–13.
4. Hildick-Smith DJ, Maryan R, Shapiro LM. Assessment of coronary flow
reserve by adenosine transthoracic echocardiography: validation with
intracoronary Doppler. J Am Soc Echocardiogr. 2002;15:984–90.
5. Saraste M, Koskenvuo J, Knuuti J, Toikka J, Laine H, Niemi P, et al. Coronary flow
reserve: measurement with transthoracic Doppler echocardiography is
reproducible and comparable with positron emissiontomography. Clin Physiol.
2001;21:114–22.
6. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson
J, Nylander S, et al. Ticagrelor enhances adenosine-induced coronary
vasodilatory responses in humans. J Am Coll Cardiol. 2013;61:723–7.
7. Michelsen MM, Pena A, Mygind ND, Frestad D, Gustafsson I, Hansen HS, et al.
Coronary flow velocity reserve assessed by transthoracic Doppler: The iPOWER
Study: Factors influencing feasibility and quality. J Am Soc Echocardiogr. 2016;
29:709–16.
8. Hozumi T, Yoshida K, Ogata Y, Akasaka T, Asami Y, Takagi T, et al.
Noninvasive assessment of significant left anterior descending coronary
artery stenosis by coronary flow velocity reserve with transthoracic color
Doppler echocardiography. Circulation. 1998;97:1557–62.
9. Saraste M, Vesalainen RK, Ylitalo A, Saraste A, Koskenvuo JW, Toikka JO, et al.
Transthoracic Doppler echocardiography as a noninvasive tool to assess
coronary artery stenoses–a comparison with quantitative coronary
angiography. J Am Soc Echocardiogr. 2005;18:679–85.
10. Haraldsson I, Gan LM, Svedlund S, Wittfeldt A, Råmunddal T, Angerås O, et al.
Non- invasive evaluation of coronary flow reserve with transthoracic Doppler
echocardiography predicts the presence of significant stenosis in coronary
arteries. Int J Cardiol. 2014;176:294–7.
11. Cortigiani L, Rigo F, Gherardi S, Bovenzi F, Molinaro S, Picano E, et al.
Coronary flow reserve during dipyridamole stress echocardiography predicts
mortality. JACC Cardiovasc Imaging. 2012;5:1079–85.
12. Nakanishi K, Fukuda S, Shimada K, Miyazaki C, Otsuka K, Maeda K, et al.
Impaired coronary flow reserve as a marker of microvascular dysfunction to
predict long-term cardiovascular outcomes, acute coronary syndrome and
the development of heart failure. Circ J. 2012;76:1958–64.
13. Cortigiani L, Rigo F, Gherardi S, Bovenzi F, Picano E, Sicari R. Prognostic value of
Doppler echocardiographic-derived coronary flow velocity reserve of left anterior
descending artery in octogenarians with stress echocardiography negative for
wall motion criteria. Eur Heart J Cardiovasc Imaging. 2015;16:653–60.
14. Kiviniemi TO, Saraste M, Koskenvuo JW, Airaksinen KE, Toikka JO, Saraste A,
et al. Coronary artery diameter can be assessed reliably with transthoracic
echocardiography. Am J Physiol Heart Circ Physiol. 2014;286:H1515–20.
15. Kiviniemi TO, Toikka JO, Koskenvuo JW, Saraste A, Saraste M, Pärkkä JP, et al.
Vasodilation of epicardial coronary artery can be measured with
transthoracic echocardiography. Ultrasound Med Biol. 2007;33:362–70.
16. Shiode N, Kato M, Nakayama K, Shinohara K, Kurokawa J, Yamagata T, et al.
Effect of adenosine triphosphate on human coronary circulation. Intern
Med. 1998;37:818–25.
17. Nijjer SS, Sen S, Petraco R, Davies JE. Advances in coronary physiology. Circ J.
2015;79:1172–84.
18. Wikström J, Grönros J, Gan LM. Adenosine induces dilation of epicardial
coronary arteries in mice: relationship between coronary flow velocity
reserve and coronary flow reserve in vivo using transthoracic
echocardiography. Ultrasound Med Biol. 2008;34:1053–62.
19. Anderson HV, Stokes MJ, Leon M, Abu-Halawa SA, Stuart Y, Kirkeeide RL.
Coronary artery flow velocity is related to lumen area and regional left
ventricular mass. Circulation. 2000;102:48–54.
20. Ling LH, Christian TF, Mulvagh SL, Klarich KW, Hauser MF, Nishimura RA, et al.
Determining myocardial viability in chronic ischemic left ventricular
dysfunction: a prospective comparison of rest-redistribution thallium 201
single-photon emission computed tomography, nitroglycerin-dobutamine
echocardiography, and intracoronary myocardial contrast echocardiography.
Am Heart J. 2006;151:882–9.
21. Takagi A, Tsurumi Y, Arai K, Ishii Y, Tanimoto K, Ishizuka N, et al. Non-
invasive assessment of coronary arterial tone using trans-thoracic Doppler
echocardiography. Circ J. 2006;70:459–62.
22. Kula M, Tutuş A, Unal S, Topsakal R, Ergin A. Technetium-99 m-tetrofosmin
imaging with incremental nitroglycerin infusion to detect severely
ischaemic but viable myocardium: a comparative study with thallium-201.
Nucl Med Commun. 2003;24:987–94.
23. Büchi M, Jenni R. Measurement of flow velocity in the coronary circulation:
requirements and pitfalls. Semin Interv Cardiol. 1998;3:45–50.
24. Morita H, Ohmori K, Matsuyama T, Mizushige K, Matsuo H. A new
noninvasive method of diagnosing vasospastic angina based on dilation
response of the left main coronary artery to nitroglycerin as measured by
echocardiography. J Am Coll Cardiol. 1996;27:1450–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wittfeldt et al. Cardiovascular Ultrasound  (2016) 14:48 Page 6 of 6
